Laboratory evaluation of selective in situ refractive cornea collagen shrinkage with continuous wave infrared laser combined with transepithelial collagen cross-linking: a novel refractive procedure

Anastasios John Kanellopoulos
LaserVision gr Institute, Athens, Greece; New York University Medical School, New York City, NY, USA

Background: This research comprised a laboratory evaluation of a novel refractive surgery technique involving sequential corneal subsurface shrinkage-driven reshaping using a continuous wave mid-infrared laser application followed by stiffening via rapid transepithelial higher fluence collagen cross-linking for shape persistence/longevity on cadaver corneas.

Materials and methods: Ten cadaver corneas were used in this study. During use, all were affixed in an artificial chamber. Thermal delivery entailed a continuous wave laser at 2013 nm wavelength, approximately 650 mW power under scanner control (about 3 mm/sec linear draw speed), with a planoconcave sapphire applanation lens cooled to 8°C. Group 1 (n = 5, myopic treatment) eyes were exposed to three concentric annuli with diameters of 3 mm, 4 mm, and 5 mm. Group 2 (n = 5, hyperopic treatment) eyes were exposed to three concentric annuli with diameters of 6 mm, 7 mm, and 8 mm. The clinical change in shape of the cornea was visualized immediately under a slit-lamp. A transepithelial higher fluence corneal collagen cross-linking step followed each thermal treatment, comprising 0.1% riboflavin drops with 0.02% benzalkonium chloride and 0.2% carboxymethylcellulose in deuterated water (D2O) applied on the epithelial corneal surface for 10 minutes. Next, each cornea was exposed to 10 mW/cm² of ultraviolet A (365 nm) light for 10 minutes. The corneas were evaluated before and after thermal remodeling and corneal collagen cross-linking for corneal topography, corneal optical coherence tomography, cornea Scheimpflug tomography, and clinical photographs.

Results: The histopathology effect was noted clinically as concentric white rings underneath the epithelium and Bowman’s membrane, with the lesion depth extending down to 400 µm in the mid stroma of the cornea. This was confirmed by corneal anterior segment optical coherence tomography. The topographic change noted was a 4–8 diopter hyperopic shift in group 1 and a 2–6 diopter myopic shift in group 2.

Conclusion: This novel refractive surgery technique appears to generate a significant refractive change (+/-) in the cornea, without affecting the epithelium or Bowman’s membrane and without any visible epithelial defect. The transepithelial collagen cross-linking used as a second step in the same procedure aims to stabilize this effect in the long term. Further clinical studies are planned to validate these initial clinical results.

Keywords: cornea collagen shrinkage, refractive cornea change, cornea collagen cross-linking, infrared laser

Introduction
Historical attempts at reshaping corneal collagen, such as conductive keratoplasty and laser thermal keratoplasty, in order to achieve a refractive change, have been studied
extensively in ophthalmology.1–14 A particular attraction of these procedures has been the nonablative tissue-sparing reshaping result, while a common concern has been stability/regression of effect, hence long-term predictability. Recently, the Keraflex® two-step procedure (Avedro, Waltham, MA) has been reported to utilize a contact probe which deposits microwave thermal energy onto the anterior cornea, inducing collagen shrinkage.14–18 A circular epithelial defect has been noted immediately postoperatively. This thermal step is sequenced by lesional collagen cross-linking in order to establish longevity of the corneal remodeling achieved by the thermal effect of this procedure.

We report herein a novel in situ thermal reshaping application in which a continuous wave infrared laser is used to create selective collagen shrinkage in the anterior to mid stroma, without affecting the corneal epithelium or Bowman’s membrane or endothelium, then applying high irradiance ultraviolet light with a customized riboflavin formulation for collagen cross-linking to stiffen collagen for persistence of this refractive effect in a laboratory model.

**Materials and methods**

Ten cadaver eyes, provided by the Eye-Bank for Sight Restoration (New York, NY) were utilized on a single-use artificial chamber (Katena Products, Inc, Denville, NJ). The corneas were carefully handled so as to not disturb their epithelium, with instillations of Vidilac preserved artificial tears (Bausch and Lomb Dublin, Ireland, see Figures 1 and 2). The corneas were imaged before and after treatment with corneal optical coherence tomography (Optovue, Freemont, CA, Figure 3), Placido disc corneal topography (Topolyzer; Wavelight, Erlagen, Germany) and a Scheimpflug cornea tomography device (Oculyzer; Wavelight; Figure 4) were used in order to establish baseline corneal parameters, ie, texture and anatomy, as well as cornea curvature and refractive power. Next, the corneas were placed under the prototype continuous wave infrared laser device articulating arm.

The novel infrared laser device consisted of a mid infrared 2013 nm laser-generating element coupled to a PC-controlled scanner (Figure 5) via a fiber and focused onto the cornea through an applanated chilled sapphire lens housed in a...
Following an applanated cooling period of 30 seconds, the treatment was started under the control of a foot switch. It should be noted that key parameters of the laser application were specified by the surgeon at the start of each exposure. The surgeon could select one, two, three, or up to seven ring speeds, and power control, significant precision of outcomes (diopters of correction) was provided by the device.

Ring diameters and the sequence of patterns with speed and power were settable on the PC screen by the surgeon. Due to such extensive flexibility in laser depth, diameter, draw...
We have done with this device for correction of myopia, we decided to place the three lesional rings at diameters of 3 mm, 4 mm and 5 mm, each planned to focus laser treatment at a depth of 100 µm and centered on the cornea.

The device was activated by a foot switch, and each ring was created through a continuous wave laser, applying the laser energy in a circular counterclockwise fashion, to create a complete circular subsurface ring lesion. First, the 3 mm diameter ring was completed, then the 4 mm diameter ring, and finally the 5 mm diameter ring. The total laser application per ring lasts about 4 seconds, and complete application of the arm on the cornea lasted under one minute (30 seconds + 12 seconds + 15 seconds). The system is designed to provide constant but selectable linear draw speeds at each diameter, thus inducing a uniform quality of lesion.

Following infrared laser delivery, cooling was continued for a further 15 seconds. Next, the applanation device was disengaged from the cornea. The cornea was then evaluated under the slit-lamp, and slit-lamp photographs were taken. The clinical effect of laser treatment was clearly evident as white opaque circular rings within the corneal stroma. There was no epithelial defect noted on the cornea surface, and corneal shrinkage noted on the slit-lamp was evaluated to be at about half the cornea depth. This was then further evaluated by corneal optical coherence tomography and corneal Placido disc-based topography and Scheimpflug tomographic mapping.

The hyperopic treatment was very similar to the myopic treatment described earlier, with the difference being that the concentric rings were applied at 6 mm, 7 mm, and 8 mm diameters from the center of the applanated cornea. On completion of laser application, the corneas were placed in a proprietary 0.1% riboflavin solution for half an hour, and then exposed to 10 mW/cm² ultraviolet light for 10 minutes to obtain corneal collagen cross-linking.

**Results**

Five corneas subjected to myopic treatment showed a very similar slit-lamp and corneal optical coherence tomography effect. Corneal shrinkage was achieved, starting at about 100 µm in depth and extending down to about 300 µm in depth, with an annulus thickness of about 800 µm. There was no change in the corneal epithelium, while corneal topography showed flattening of the cornea (Figure 10, treated cornea does not stain with fluorescein), creating a hyperopic shift, which ranged from 4 to 8 diopters with a mean change of 6.5 diopters (Figure 11, corneal optical coherence tomography...
showing corneal shrinkage as a dense hyper-reflective spot. Figures 12 and 13 show representative myopic treatment (pre, post, and difference).

Similar results were found in the hyperopic group, in which the myopic shift (steepening) of the central cornea was found to be 2–6 diopters, with an average diopter change of 4.2 in the central cornea. Figure 14 shows a representative hyperopic treatment (pre-, post-, and difference). Clinical pictures of the corneas following treatment are shown in Figure 15.

**Discussion**

We hypothesize that quality of vision outcome is related to quality of the lesion, including its position and size characteristics within the three-dimensional stromal collagen matrix. We have seen that shrinkage from thermal lesions at a programmable diameter/depth can be titrated to control the changes in the shape of the corneal surface that persist following cross-linking. This epithelium-sparing, reshaping, and stabilizing technique is clearly a novel approach in refractive manipulation of the cornea. Our small laboratory study shows a remarkable refractive change immediately after delivery that was relatively consistent in all the corneas.

An interesting finding was the fact that laser application did not affect the corneal epithelium or in most cases the Bowman’s membrane at all. The actual location of the ring lesion was very close to the planned dimensions. There was no abrasion or thermal effect on the corneal epithelium and thus the nerve plexus was likely to have been preserved. Laser application appeared to cause collagen shrinkage that could be constrained (‘endothelium-sparing’) as needed to a corneal depth of approximately 50%. This was confirmed on evaluation of the cornea after the procedure, as well as by corneal optical coherence tomography.

We also used transepithelial higher fluence corneal collagen cross-linking in order to help maintain an intact epithelium, which is the unique aspect of this procedure. Although transepithelial corneal collagen cross-linking may potentially affect epithelial cell viability, it is nevertheless not associated with an obvious clinical epithelial defect. We have previously reported the clinical safety and efficacy of higher fluence corneal collagen cross-linking for progressive keratoconus. We used transepithelial corneal collagen cross-linking as a means of stabilizing the refractive effect of corneal shrinkage, as described elsewhere.8 In order to perform the transepithelial corneal collagen cross-linking, we used 0.1% riboflavin sodium phosphate drops containing benzalkonium chloride. The purpose of these drops was to loosen the hemidesmosome links between the epithelial cells of the cornea and to allow the large riboflavin molecule to sink into the corneal stroma and achieve collagen cross-linking.

The purpose of sequencing collagen cross-linking in the thermal procedure is to enhance persistence of the collagen shrinkage effect from continuous wave laser application. This procedure has several advantages. One is the ability to titrate the amount of refractive change (+/-) applied to the cornea via number and diameter of the thermal rings applied. Another advantage is that the delivery can be “free form”, i.e. these rings can be moved on the applanated surface of the cornea and potentially be centered over any ectatic part of the cornea, and shrink that part of the cornea and flatten the ectasia. “Bow tie” patterns for astigmatic corrections, reported elsewhere, are easily feasible.
Figures 12 and 13 Both these images illustrate the pre- (center) and post- (right) laser treatment corneal topography, as well as the difference (left). The significant central and homogenous hyperopic shift confirms that myopic treatment has been achieved.
We have introduced and evaluated clinically the use of topography-guided excimer laser normalization techniques combined with corneal collagen cross-linking, i.e. the Athens protocol, in the treatment of corneal ectasia associated with keratoconus, iatrogenic ectasia, and recently severe corneal scarring.21–27 The novel treatment described herein may become an alternative to the Athens protocol, serving potentially the same purpose of normalizing corneal irregularity with customized toric and spherical infrared laser cornea refractive modification and stabilizing the ectasia with combined corneal collagen cross-linking, without tissue removal or corneal thinning.

Although not studied herein, the pachymetry requirements of such a treatment may be as low as 350 µm in vivo, allowing its application in extreme ectasia. The main difference between this technique and the Keraflex is in essence the lack of epithelial injury and highly titratable nature of the laser application and therefore corneal shrinkage.

**Conclusion**

This novel laser and corneal collagen cross-linking treatment appears to be able to both flatten and steepen the cornea, depending on the diameter and depth of laser application, and coupled with transepithelial collagen cross-linking, may provide a novel nonincisional, nonimplanted, sutureless, and essentially pain-free procedure (due to no epithelium defect). Very little discomfort is anticipated in real clinical use postoperatively, and there is a very low risk of infectious complications involving the cornea. Further clinical studies are needed to validate these findings in clinical practice and potentially make this novel procedure a valid alternative for the correction of myopia, hyperopia, astigmatism, and presbyopia, and potentially also as a treatment for stabilization of ectasia.

**Disclosure**

This research was presented in part at the 15th Winter Meeting of the European Society of Cataract and Refractive
Surgeons, Istanbul, Turkey, February 18–20, 2011. The author has served in the past as a nonpaid consultant for Seros Medical (Palo Alto, CA) and is a consultant for Alcon/Wavelight. The novel infrared laser device, technical assistance, and study design advice were generously provided by Satish Herakar, co-founder of Seros Medical.

References